Laurence Legeai-Mallet is currently Director of Research at Imagine Institute-Paris Descartes University. She received her PhD in genetic from University of Paris V, she is a member of International skeletal dysplasia Society, European Skeletal Dysplasia Network and the French reference center of bone dysplasias. She has been involved in the field of skeletal disease since 1993. Her research field ranges from identification of disease genes involved in cartilage and bone diseases, in understanding bone development and skeketal diseases to the development of therapeutic approaches. In 2009, she initiated therapeutic approaches for osteochondrodysplasias through collaboration in both academic chemistry laboratory (Paris Descartes University) and pharmaceutical companies. In 2012, in collaboration with BioMarin, she reported the therapeutic potential of a novel natriuretic peptide C analogue (BMN111) as the first investigational therapy for the most frequent dwarfism, achondroplasia.
27 - 30 Jun 2015